Clinical trials

122. Disclosure of the Results of Clinical Trials: Case Study of Tamiflu and Implications for Statins

One of the key issues to emerge from the recent spat between Sir Rory Collins and the BMJ about statins (1) has been the refusal of the Cholesterol Treatments Trialists’ Collaboration (CTT) at Oxford University to allow open access to the original clinical trial data. The independent panel set up by the editor of the […]

122. Disclosure of the Results of Clinical Trials: Case Study of Tamiflu and Implications for Statins Read More »

85. More about the Drug Companies

If drugs are to be effective and safe to use, it is axiomatic that the regulatory process has the power, resources and competence to be capable of validating all the information which has to assessed before official approval can be granted. Genuine doubts have frequently been expressed which indicate that the regulation of drugs is

85. More about the Drug Companies Read More »

Scroll to Top